TCGA-CV-A45O-01A-21R-A24H-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- CHOLESTEROL_HOMEOSTASIS+0.450
- INTERFERON_GAMMA_RESPONSE+0.440
- TNFA_SIGNALING_VIA_NFKB+0.330
- P53_PATHWAY+0.290
- INFLAMMATORY_RESPONSE+0.270
- ESTROGEN_RESPONSE_EARLY+0.250
- COMPLEMENT+0.240
- HYPOXIA+0.240
- BILE_ACID_METABOLISM+0.230
Top 10 suppressed
- E2F_TARGETS-0.700
- MYC_TARGETS_V2-0.680
- G2M_CHECKPOINT-0.560
- MYC_TARGETS_V1-0.560
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- DNA_REPAIR-0.350
- OXIDATIVE_PHOSPHORYLATION-0.310
- ANGIOGENESIS-0.290
- PANCREAS_BETA_CELLS-0.180
- MITOTIC_SPINDLE-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2278849 | — | — | 0.891 |
| 2 | 0429cf04-6e5c-41dd-b4a9-4f7ad15d15bc | — | — | 0.882 |
| 3 | TCGA-69-8254-01A-11R-2287-07 | — | cohortA1 | 0.851 |
| 4 | TCGA-F7-A50G-01A-11R-A266-07 | — | — | 0.851 |
| 5 | BS_BN986DF6 | pilocytic astrocytoma | — | 0.840 |
| 6 | TCGA-CN-6013-01A-11R-1686-07 | — | — | 0.839 |
| 7 | ERR2208952 | — | — | 0.834 |
| 8 | SRR12475139 | — | — | 0.833 |
| 9 | TCGA-CR-6492-01A-12R-2081-07 | — | — | 0.823 |
| 10 | TCGA-EW-A1PE-01A-11R-A144-07 | — | B | 0.820 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.450 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.290 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.270 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.250 | Inavolisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.120 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |